PulmoPharma has so far been supported by public and private investors. The team behind PlumoPharma ApS has completed a pallet of proof-of-concept studies on various microorganisms, among others with help from the Department of Microbiology at Aarhus University Hospital, Danish Technological Institute and Statens Serum Institut, Denmark. The studies show that Puldium™ has a unique effect against resistant Aspergillus fumigatus types, which is completely novel and unique.

The target group is mainly patients infected with azole resistant Invasive Aspergilus fumigatus but also allergic bronchopulmonary aspergillosis (ABPA).

There are p.t. initiated pre-clinical studies at various European universities so that evidence can be gathered to obtain permission to initiate human clinical studies in this patient group.

The toxicological studies are being reviewed and are expected to be launched soon. In this connection, PulmoPharma is looking for partners with major medical companies in this area, as collaborator, investor and/or development partners.